|
KMID : 0939920090410020067
|
|
대한암학회지
2009 Volume.41 No. 2 p.67 ~ p.72
|
|
|
Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
|
|
Hong Min-Hee
Chung Hyun-Cheol
Ahn Joong-Bae
Chon Hong-Jae
Ahn Jung-Ryun
Shin Sang-Joon
Rha Sun-Young
Kim Hyo-Song
Kim Chan
|
|
|
Abstract
|
|
|
Purpose: The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).
Materials and Methods: Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.
Results: Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients(18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serumcreatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia(69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-footsyndrome (9.2%).
Conclusion: Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
|
|
|
KEYWORD
|
|
|
Renal cell carcinoma, Sunitinib, Korea, Efficacy, Toxicity
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|